Latest Celosia Therapeutics News & Updates

See the latest news and media coverage for Celosia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Celosia Therapeutics (Celosia)

Gene therapy company developing treatments for neurological diseases

celosiatx.com

Headquarters: Sydney, Australia
Founded year: 2022
Company type: Private company
Number of employees: 1–10
Industry: Pharmaceuticals

Last updated Today

Latest news about Celosia Therapeutics (Celosia)

In short: Celosia dosed its first patient in a Phase 1 trial for CTx1000, a gene therapy targeting Amyotrophic Lateral Sclerosis.

Company announcements

May 4 Celosia

Celosia Therapeutics doses first patient in Phase 1 study

The study tests CTX 1000's safety and efficacy for ALS patients at Macquarie University Hospital. Professor Lars Ittner highlights this milestone after 17 years of development.

March 24 Celosia

Celosia Therapeutics doses first patient in Phase 1b KOANEWA trial

The trial evaluates CTx1000 gene therapy targeting TDP-43 in ALS patients at Macquarie University Hospital. CEO highlights milestone for ALS community.

February 16 Celosia

Celosia secures second U.S. patent for CTx1000 therapy

This strengthens IP foundation amid clinical preparation for first-in-human dosing. The team advances toward patient impact.

2 December 2025 Celosia

Celosia Therapeutics mourns Iomar Barrett's passing

Iomar Barrett was a courageous ALS patient, visionary Series A investor, and steadfast supporter who shaped the company's foundation and mission for ALS therapies.

Media coverage

March 23 Morningstar

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 23, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing...

17 February 2025 The Australian

Macquarie University spin-out Celosia Therapeutics nabs $16.8m to take ALS treatment to trial

Celosia Therapeutics, a Macquarie University spin-out, has picked up the funds by way of Uniseed for its lead treatment - called CTX-1000 - which is...

Never miss news about Celosia

Track Celosia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Celosia competitors & trending companies

Browse news for competitors to Celosia and other trending companies.